Optimizing Cough Rehabilitation Through Combined Cough Skill Training and Transcutaneous Spinal Cord Stimulation (Optimizing Cou)

November 17, 2026 updated by: University of Florida

The goal of this clinical trial is to evaluate the effects of combining cough training with low-level electrical stimulation to the neck (tsDCS) in healthy adults and adults with neurological diseases. The main questions it aims to answer are:

  • Is using tsDCS during cough training safe, tolerable, and acceptable to participants?
  • What tsDCS settings are most effective for pairing with cough training? Researchers will compare sham stimulation with active tsDCS to see if tsDCS enhances cough gains. Before and after each testing session, participants will complete breathing, coughing, and respiratory-strength training.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Study Purpose and Background People with neurodegenerative diseases frequently experience reduced cough function (hypotussia) and swallowing difficulties (dysphagia), which negatively impact quality of life and increase the risk of pneumonia, a leading cause of death in these populations. While behavioral exercises like cough training can help improve airway protection, people with these diseases often struggle to perform them with the high intensity required to trigger lasting brain and nerve adaptation (neuroplasticity).

To overcome this limitation, this pilot study investigates a novel, non-invasive combinatorial approach: pairing Cough Skill Training (CST) with transcutaneous spinal direct current stimulation (tsDCS) applied to the neck. The theory is that spinal stimulation enhances communication between the brain and muscles, optimizing the outcomes of training. Because this combined intervention has not been tested before, this initial research aims to establish its overall feasibility and compare different stimulation settings in healthy adults before future translation to clinical patient populations.

Study Design and Methods This study is an initial pilot trial utilizing a randomized crossover design involving 16 healthy adult participants aged 40 to 85 years with normal respiratory function.

  • Screening & Familiarization (Visit 1): Participants undergo baseline screening, including health history reviews and spirometry (pulmonary function testing). They are also familiarized with the testing and training activities.
  • Intervention Sessions: Across separate intervention visits separated by a 6-week washout period, participants receive 20 minutes of neck-based tsDCS paired with CST. During active stimulation, current is delivered continuously, whereas sham stimulation provides brief ramping periods without sustained current. CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).
  • Assessments: Researchers record vital signs, breathing tests, airway occlusions (to measure drive to breathe), maximum respiratory pressure tests. Exploratory measures, such as saliva swallowing patterns and how long participants can produce a vowel sound, are also tracked.

Aims:

  • Aim 1: Feasibility and acceptability will be evaluated by the participants' ability to complete all training tasks simultaneously with stimulation, scores from the Acceptability of Intervention Measure (AIM), participant ability to blind/detect sham versus active treatment, and perceived exertion, task difficulty, and stimulation intensity ratings.
  • Aim 2: Cough and respiratory performance will be measured by the change in cough peak expiratory flow rate (PEFR) from baseline, along with CST performance accuracy, other cough, resting breathing, and respiratory strength parameters.

Study Type

Interventional

Enrollment (Estimated)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: May Smith-Hublou, PhD, SLP
  • Phone Number: 352-273-6855
  • Email: maysmith@ufl.edu

Study Contact Backup

  • Name: Barbara K Smith, PhD, PT
  • Phone Number: 352-294-5315

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32610
        • University of Florida
        • Contact:
        • Principal Investigator:
          • May Smith-Hublou, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Forced vital capacity (FVC) ≥ 80% predicted based on age/sex

Exclusion Criteria:

  • neurological disease
  • respiratory disease including acute respiratory infection with cough during past week
  • Pregnancy
  • metallic implants in the spine
  • cardiac pacemaker
  • use of sodium channel blockers, calcium channel blockers, and/or NMDA receptor antagonists

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham Stimulation

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

Experimental: Cathodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

Experimental: Anodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Completion of training tasks with simultaneous stimulation
Time Frame: During training

Measured as percentage of sessions in which both interventions can be completed simultaneously.

During training
Peak Cough Flow
Time Frame: Baseline, immediate post-single-treatment measurement

The highest rate of airflow generated during a volitional cough

Baseline, immediate post-single-treatment measurement

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability of Intervention Measure (AIM)
Time Frame: Immediate post-single-treatment measurement

Participants will rate favorability of treatment procedures. This scale consists of 4 items rating acceptability using a 1-5 Likert Scale, with a combined total score range of 4-20. A score of 1 represents "completely disagree," and a score of 5 represents "completely agree." Thus, a higher score reflects a more favorable experience.

Immediate post-single-treatment measurement

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Airway occlusion pressure (P0.1)
Time Frame: Baseline vs immediate post-single-treatment

The change in air pressure at the opening of the airway (mouth and nose) in the first 100 ms of a breath. This estimates neural drive to breathe.

Baseline vs immediate post-single-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: May Smith-Hublou, PhD, University of Florida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

October 15, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • IRB202600626

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Participant data that underlie the results reported in this article after deidentification.

IPD Sharing Time Frame

9 months and ending 36 months following article publication.

IPD Sharing Access Criteria

Investigators whose proposed use of the data has been approved by an independent review committee.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.